Kidney Week

Abstract: SA-PO252

Modulation of Circulating Endothelial Progenitor Cells by Erythropoiesis-Stimulating Agent in Patients with Hemodialysis

Session Information

• Anemia and Iron Metabolism: Clinical
  November 09, 2019 | Location: Exhibit Hall, Walter E. Washington Convention Center
  Abstract Time: 10:00 AM - 12:00 PM

Category: Anemia and Iron Metabolism

• 202 Anemia and Iron Metabolism: Clinical

Authors

• Naito, Takashi, Tokyo Rosai Hospital, Yokohama, Japan

Takashi Naito,

• Nitta, Kosaku, Tokyo Women's Medical University, Shinjuku-ku, TOKYO, Japan

Kosaku Nitta,

Background

Recent studies have suggested that erythropoiesis stimulating agent (ESA) may accelerate not only angiogenesis but also vasculogenesis, beyond erythropoiesis

Methods

We conducted a 12-week prospective study in 42 dialysis patients; 11 patients were treated with recombinant human erythropoietin (rhEPO) (EPO group, 5487.5 ± 735.1 IU/week), 11 patients with darbepoetin (DA) (DA group, 41.6 ± 4.7 µg/week), 10 patients with epoetin β pegol (CERA group, 49.5 ± 16.5 µg/week ) and 10 patients with no ESAs (no-ESA group). Vascular mediators comprising EPCs, vascular endothelial growth factor, matrix metalloproteinase-2 (MMP-2), and high-sensitivity C-reactive protein were measured at 0 and 12 weeks. EPCs were measured by flow cytometry as CD45^lowCD34⁺CD133⁺ cells.

Results

In the EPO and CERA group, EPC count increased significantly from 0 to 12 weeks in a dose-dependent manner (EPO; r = 0.77, p = 0.01, CERA; r = 0.72, p = 0.01 ). In the DA group, the EPC number did not change at 12 weeks. Furthermore, the serum levels of the above biomarkers except EPC were not affected by ESA in all groups.

Conclusion

We speculate that the pleiotropic effects of each ESA types beyond their hematopoietic effects may differ in ESKD patients.

Funding

• Clinical Revenue Support